Precision Neuroscience Expands Layer 7 Cortical Brain-Computer Interface Trials to Cleveland Clinic Abu Dhabi
Following its $250 million Series D funding round, brain-computer interface developer Precision Neuroscience has signed a two-year memorandum of understanding with Cleveland Clinic Abu Dhabi (CCAD) and Abu Dhabi's Department of Health to launch its first international clinical study site, Neurofounders' Yael Lissack reported on November 9, 2026.
The international study will evaluate Precision's FDA-cleared Layer 7 Cortical Interface—a postage-stamp-sized thin-film array packing 1,024 surface electrodes that read electrical signals from the cerebral cortex without penetrating brain tissue. Cleared by the U.S. Food and Drug Administration in 2025 for temporary monitoring of up to 30 days, Layer 7 will be tested at CCAD in two adult neurosurgical cohorts: intraoperative brain mapping during surgery and post-operative hospital monitoring stays of up to 30 days.
Chief Clinical Officer Jayme Strauss told Neurofounders that Precision has already assembled a neural-activity atlas from 70 U.S. patients and is using the multi-country clinical data to prepare for a future Class III chronic permanent-implant trial.
neurofounders.co · Read the original ↗
More about biohacking
Synchron Pauses Stentrode Brain-Computer Interface Trial Enrollment Over Lead Performance Issue
Endovascular brain-computer interface developer Synchron has voluntarily paused enrollment in clinical trials of its second-generation wireless Stentrode implant after identifying a performance proble...
Neuralink Reaches 26 Brain-Implant Recipients With Outdoor Wheelchair Control and 75-WPM Speech Decoding
At least 26 clinical trial participants have received Neuralink's intracortical N1 brain-computer interface (BCI) implant as of November 2026, with recent milestones spanning outdoor powered-wheelchai...
Cognixion Launches NIH-Funded Clinical Trial of Non-Invasive EEG and AR Brain-Computer Interface
Santa Barbara neurotechnology developer Cognixion has launched CHOICE, an NIH-funded 12-week clinical trial enrolling 30 adults with amyotrophic lateral sclerosis (ALS) to evaluate its non-invasive el...